A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are underway, and life-saving treatments have been developed.

Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...

One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the global genome market is expected to expand at a compound annual ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...

CRISPR Therapeutics AG CRSP shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...